OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
OXURION announces its presence at the Paris SmallCapevent on March 28, 2024.
Read more:
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
Author Archives: admin
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.
See more here:
BioCryst to Present at Upcoming Investor Conferences
Praxis Precision Medicines to Host PRAX-628 Program Update
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET
See the original post:
Praxis Precision Medicines to Host PRAX-628 Program Update
OpGen Announces Acquisition of Preferred Stock by David Lazar
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.
See more here:
OpGen Announces Acquisition of Preferred Stock by David Lazar
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.
Excerpt from:
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023 QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023
Read more from the original source:
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2023.
Read more here:
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2023, and recent business highlights.
Here is the original post:
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolR?-expressing cancers -
View original post here:
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones